ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
1.32%
Brent Oil
82.275
0.37%
Bitcoin
65,924.99
-1.25%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) News

Royalty Pharma (RPRX)

Royalty Pharma PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RPRX
DateTimeSourceHeadlineSymbolCompany
10/06/202421:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
06/06/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
04/06/202422:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPRXRoyalty Pharma PLC
04/06/202421:57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
04/06/202421:15GlobeNewswire Inc.Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
03/06/202422:15GlobeNewswire Inc.Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured NotesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202421:59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202414:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPRXRoyalty Pharma PLC
03/06/202413:39Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RPRXRoyalty Pharma PLC
29/05/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
28/05/202412:10GlobeNewswire Inc.Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionNASDAQ:RPRXRoyalty Pharma PLC
22/05/202421:10GlobeNewswire Inc.Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
22/05/202421:00GlobeNewswire Inc.Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
16/05/202422:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RPRXRoyalty Pharma PLC
13/05/202413:15GlobeNewswire Inc.Royalty Pharma to Present at Upcoming Investor ConferencesNASDAQ:RPRXRoyalty Pharma PLC
09/05/202414:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPRXRoyalty Pharma PLC
09/05/202412:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
09/05/202412:00GlobeNewswire Inc.Royalty Pharma Reports First Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
09/05/202411:45GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Sanofi’s FrexalimabNASDAQ:RPRXRoyalty Pharma PLC
19/04/202413:15GlobeNewswire Inc.Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:RPRXRoyalty Pharma PLC
17/04/202413:15GlobeNewswire Inc.Royalty Pharma Declares Second Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
28/02/202421:15GlobeNewswire Inc.Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:RPRXRoyalty Pharma PLC
15/02/202414:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RPRXRoyalty Pharma PLC
15/02/202412:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
15/02/202412:30GlobeNewswire Inc.Royalty Pharma Reports Q4 and Full Year 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
06/02/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
30/01/202421:15GlobeNewswire Inc.Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024NASDAQ:RPRXRoyalty Pharma PLC
19/01/202413:15GlobeNewswire Inc.Royalty Pharma Announces Dividend IncreaseNASDAQ:RPRXRoyalty Pharma PLC
08/01/202412:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
08/01/202412:00GlobeNewswire Inc.Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:RPRX

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
AAZ
Anglo Asian Mining
LSE
HE1
Helium One Global
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
THG
Thg
LSE
TERN
Tern
LSE
EEE
Empire Metals
LSE
BIRD
Blackbird
LSE
BT.A
Bt
LSE
ENET
Ethernity Networks
LSE
VAST
Vast Resources
LSE
GGP
Greatland Gold
LSE
RPI
Raspberry Pi
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved